A Deep Pipeline of Allogeneic, Off-The-Shelf, Virus-Specific T Cell (VST) Therapies

A large number of patients are fighting viral infections or diseases with limited or no treatment options. To address this, we are advancing a pipeline of allogeneic, off-the-shelf VSTs to treat or prevent life-threatening viral diseases.
*Prevention of adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), JC virus (JCV).
Target Population
Target Indication
Preclinical
POC Trial
(Phase 1b/2)
Pivotal Trial
(Phase 3)
Allo-HSCT
Treatment of vHC
Allo-HSCT
Treatment of AdV
Allo-HSCT
Multi-virus Prevention*
Kidney Transplant
Treatment of BKV
Solid Organ Transplant
Multi-virus Prevention*
Multi-VSTs targeting Human Metapneumovirus (hMPV), Influenza (Flu), Parainfluenza Virus (PIV), and Respiratory syncytial virus (RSV).
*High-risk general population: immunocompromised cancer patients, the elderly, and very young.
Target Population
Target Indication
Preclinical
POC Trial
(Phase 1b/2)
Pivotal Trial
(Phase 3)
Allo-/Auto-HSCT
Treatment of hMPV,
Flu, PIV, RSV
High-risk general
population*
Treatment of hMPV,
Flu, PIV, RSV
Single-VST targeting Hepatitis B (HBV).
Target Population
Target Indication
Preclinical
POC Trial
(Phase 1b/2)
Pivotal Trial
(Phase 3)
Chronic HBV
HBV Cure
Single-VST targeting SARS-CoV-2.
Target Population
Target Indication
Preclinical
POC Trial
(Phase 1b/2)
Pivotal Trial
(Phase 3)
Immunocompromised
Immuno-
compromised
COVID-19 Treatment
Compassionate
Use Access
Definitions
Allo-HSCT: allogeneic HSCT; Auto-HSCT: autologous HSCT; POC: Proof-of-concept; High-risk general population: immunocompromised cancer patients, the elderly, and very young.

We Treat Individuals at High Risk

Our allogeneic, off-the-shelf VST candidates benefit patients with T cell deficiencies, including transplant recipients, immunocompromised cancer patients, the elderly, and the very young, who are at a higher risk of the devastating consequences of viral diseases.
BK Virus
Cytomegalovirus
Adenovirus
Epstein-Barr Virus
Human Herpesvirus-6
Parainfluenza Virus
Human Metapneumovirus
Influenza Virus
Respiratory Syncytial Virus
SARS-CoV-2
Hepatitis B Virus
Bladder
Severe hemorrhagic cystitis
Urinary obstruction
Cystectomy
Brain
Severe encephalitis
Seizure
Memory defect
Progressive Multifocal Leukoencephalopathy
Kidneys
Nephritis
Acute/chronic renal failure
End stage renal disease
Lungs
Pneumonia
Bronchitis
Respiratory failure
Eyes
Retinitis
Blindness
Liver
Chronic hepatitis
Liver cirrhosis
Hepatocellular Carcinoma
Small/Large Intestine
Colitis
Ulceration / perforation
Intestinal bleeding
Malignancy
Kaposi sarcoma
Primary Effusion
Lymphoma (PEL)

AlloVir is the global leader in developing VST immunotherapies

We develop highly innovative, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies designed to prevent and treat life-threatening viral diseases.

Our Pipeline

Our allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses as treatment or prevention.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

We are united in purpose around a singular mission to prevent and defeat life-threatening viral diseases.
meet
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?